top of page

Release Therapeutics to present at the Emerging Biotech Company Track, Swiss Biotech Day 2025 (11 April 2025)
We are thrilled to announce that Release Therapeutics has been selected to present at the Emerging Biotech Company Track at Swiss Biotech...
3 hours ago1 min read
2 views
0 comments

Shining a light on MLD and the Urgency for Change: Rare Disease Day (28 February 2025)
Rare Disease Day isn’t about numbers. It’s about people—the individual and their family whose world is forever shifted by a diagnosis...
Feb 281 min read
15 views
0 comments

Key Takeaways from the 21st Annual WORLDSymposium on Lysosomal Disease Research (11 February, 2025)
The field of lysosomal disorders is making great strides, with breakthroughs in basic science paving the way for potential new...
Feb 111 min read
20 views
0 comments

Meet Release Tx at the WORLDSymposium™ on Lysosomal Disease Research (3–7 February 2025)
We are thrilled to announce that Release Therapeutics is attending the 21st annual WORLDSymposium ™ on Lysosomal Disease Research held...
Feb 31 min read
18 views
0 comments

Release Therapeutics Announces New CEO to Advance Groundbreaking Treatment for Brain Disorders (30 January 2025)
Dr. Julien Grogg will Lead the Company's Transition to Clinical Development Building on Promising Primate Study GENEVA, 30 January, 2025...
Jan 303 min read
166 views
0 comments

Release Tx Announces Scientific Advisory Board (SAB; 23 December 2024)
We are thrilled to introduce Release Tx's Scientific Advisory Board (SAB), which brings together leading experts in leukodystrophies,...
Dec 23, 20241 min read
50 views
0 comments

Release Tx to attend 134th SICTIC Investor Day at IMD Lausanne (28 November 2024)
All of us at Release Tx are excited to be participating in the the 134th SICTIC Investor Day at IMD, Lausanne on 28 November 2024, where...
Nov 21, 20241 min read
33 views
0 comments


Release Tx to attend Lenz & Staehelin Founders’ Evening (20 November 2024)
We’re pleased to announce that Release Therapeutics will be attending Founders’ Evening, organised by Lenz & Staehelin on 20 November at...
Nov 19, 20241 min read
18 views
0 comments

Release Tx to attend Cell Press Tumor Immunology and Immunotherapy Symposium (11 – 12 November 2024)
We are pleased to announce that Release Tx will participate in the upcoming Cell Press LabLinks Tumor Immunology and Immunotherapy...
Nov 7, 20241 min read
12 views
0 comments

Meet Release Tx at the ESGCT Congress in Rome (22–25 October 2024)
Release Therapeutics is pleased to announce our participation in the European Society of Gene and Cell Therapy (ESGCT) Congress that will...
Oct 17, 20241 min read
14 views
0 comments

Meet Release Tx at FutureHealth Lausanne 2024 (1 October 2024)
Release Therapeutics is thrilled to announce our participation in FutureHealth Lausanne 2024, which kicks off at the SwissTech Convention...
Sep 25, 20241 min read
29 views
0 comments

Release Therapeutics Secures CHF 3.3 Million in Seed Funding
The funding follows the Company’s first preclinical results in metachromatic leukodystrophy and will be invested in studies in non-human...
Aug 6, 20242 min read
176 views
0 comments


Release Tx Announces Research Collaboration with Paris Brain Institute to Treat Metachromatic Leukodystrophy (MLD) and First Preclinical Results
We are thrilled to announce our strategic collaboration with Paris Brain Institute to explore the potential of our cutting-edge cell...
Jul 19, 20243 min read
172 views
0 comments

Press Release: Release Therapeutics Announces New CEO to Drive Best-in-Class CNS Innovation
Release Tx Announces New CEO, aligning with the company’s recent pivot towards treating genetic disorders of the CNS without gene therapy
Jun 27, 20242 min read
116 views
0 comments

Release Therapeutics publishes cutting-edge research in Cell Press
Release Therapeutics publishes cutting-edge research in Cell Press
Jun 18, 20247 min read
165 views
0 comments

Treating Genetic Disorders of the CNS without Gene Therapy (or what we’ve been up to here at Release Therapeutics)
Release Therapeutics' strategic pivot towards treating genetic disorders of the central nervous system without gene therapy.
Jun 15, 20246 min read
198 views
0 comments

Meet us online at RESI Europe (18-19 June 2024)
Release Therapeutics is excited to announce our participation in the virtual partnering segment of RESI Europe, Barcelona from June...
Jun 14, 20241 min read
13 views
0 comments

Meet us at the WORLDSymposium
Release Tx will join the 20th annual WORLDSymposium in San Diego. https://worldsymposia.org/
Jan 13, 20241 min read
21 views
0 comments

Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells drives tumor response and prolongs survival in a colorectal cancer model
AACR American Association for Cancer Research Orlando Florida Poster Grogg et al. 2023. iScience. Engineering a versatile and retrievable...
Oct 20, 20231 min read
23 views
0 comments


MaxiVAX transitions into Release Tx
We are pleased to announce that, with the recent progress in the development of its unique platform technology, MaxiVAX is morphing into...
Sep 15, 20231 min read
83 views
0 comments
bottom of page